Novartis Obtains Approval for Additional Indication of Pediatric Chronic Heart Failure for Angiotensin Receptor Neprilysin Inhibitor (ARNI) Entresto Tablet®

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that Novartis Pharma K.K. (Novartis Pharma) has obtained approval for the additional treatment indication of pediatric chronic heart failure for an angiotensin receptor neprilysin inhibitor (ARNI), Tablets 50 mg, 100 mg, and 200 mg (generic name: sacubitril valsartan sodium hydrate, hereinafter Entresto). This drug is the first in Japan to receive dosage and administration approval for the indication of chronic heart failure in pediatric patients.Entresto® In Japan, activities to provide information on Entresto to healthcare professionals will be conducted by Novartis Pharma and Otsuka based on a co-promotion agreement. :Entresto Tablets 50 mg (Entresto Tablets)Entresto Tablets 100 mgEntresto Tablets 200 mgSacubitril Valsartan Sodium HydrateEntresto Tablets 50 mg, 100 mg, 200 mgChronic heart failureUse only in patients receiving standard treatment for chronic heart failure.Product name ®® ® ® Nonproprietary name: Indications* (underline denotes additions): Adults Children Chronic heart failure HypertensionEntresto Tablets 100 mg, 200 mg * (Underlines denote additions.):Chronic heart failureThe usual adult starting dose is 50 mg of sacubitril valsartan administered orally twice daily. If tolerated, dosage should be increased stepwise to 200 mg at the intervals of 2 to 4 weeks. A single dose is 50 mg, 100 mg, or 200 mg, and either dose is orally administered twice daily. The dosage should be reduced according to patient's tolerability. Dosage and Administration The usual starting dose of sacubitril valsartan for children aged ≥ 1 year is administered orally twice daily according to body weight as shown in the table below. If tolerated, dosage should be increased stepwise at 2~4 week intervals. The dosage should be reduced according to patient's tolerability. HypertensionThe usual adult dosage is 200 mg of sacubitril valsartan administered orally once daily. The dose may be adjusted according to the patient's age and symptoms. The maximum dose is 400 mg once daily. Novartis Pharma K.K. nRecipient of Marketing Authorizatio:

The release as fetched from its publisher. otsuka.co.jp ↗